Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 12, Issue 3, Pages 454
Publisher
MDPI AG
Online
2022-03-14
DOI
10.3390/jpm12030454
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of GLP-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
- (2021) Paul M. Ryan et al. JOURNAL OF PEDIATRICS
- Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
- (2021) Donna Shu-Han Lin et al. DIABETOLOGIA
- Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?
- (2021) Theocharis Koufakis et al. Expert Review of Clinical Pharmacology
- Safety of Semaglutide
- (2021) Mark M. Smits et al. Frontiers in Endocrinology
- Type 2 diabetic women are not small type 2 diabetic men: Sex-and-gender differences in antidiabetic drugs
- (2021) Ilaria Campesi et al. CURRENT OPINION IN PHARMACOLOGY
- Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
- (2020) Valeria Raparelli et al. Journal of the American Heart Association
- Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
- (2020) Elvira D’Andrea et al. Cardiovascular Diabetology
- Gender differences in adverse event reports associated with antidiabetic drugs
- (2020) Kyung-In Joung et al. Scientific Reports
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- GLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
- (2020) Karan R. Chadda et al. Obesity Reviews
- Navigating the “MACE” in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits
- (2019) Christopher Hupfeld et al. DIABETES OBESITY & METABOLISM
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- (2019) Marco Castellana et al. Scientific Reports
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
- (2019) Maria Mirabelli et al. International Journal of Environmental Research and Public Health
- Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
- (2018) Kristin C. C. Petri et al. DIABETES OBESITY & METABOLISM
- Gender differences in glucose homeostasis and diabetes
- (2018) Franck Mauvais-Jarvis PHYSIOLOGY & BEHAVIOR
- Sex differences underlying pancreatic islet biology and its dysfunction
- (2018) Maureen Gannon et al. Molecular Metabolism
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- The Pathophysiology of Gestational Diabetes Mellitus
- (2018) Jasmine Plows et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
- (2016) Rune V. Overgaard et al. CLINICAL PHARMACOKINETICS
- Gastrointestinal safety across the albiglutide development programme
- (2016) L. A. Leiter et al. DIABETES OBESITY & METABOLISM
- Exposure-response analyses of liraglutide 3.0 mg for weight management
- (2016) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes
- (2016) Yukiko Onishi et al. ENDOCRINE JOURNAL
- Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
- (2016) Alexandra Kautzky-Willer et al. ENDOCRINE REVIEWS
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus
- (2016) Huibiao Quan et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight
- (2016) Heike Vogel et al. NEUROPHARMACOLOGY
- Sex and estrogens alter the action of glucagon-like peptide-1 on reward
- (2016) Jennifer E. Richard et al. Biology of Sex Differences
- Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States
- (2016) Emily Durden et al. JOURNAL OF MEDICAL ECONOMICS
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
- (2015) Jeanne S. Geiser et al. CLINICAL PHARMACOKINETICS
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
- (2015) Michael A. Nauck et al. DIABETES CARE
- Enumerating β-Cells in Whole Human Islets: Sex Differences and Associations With Clinical Outcomes After Islet Transplantation
- (2015) Enza Marchese et al. DIABETES CARE
- Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
- (2015) M. Sue Kirkman et al. DIABETES CARE
- Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
- (2015) Eusebio Chiefari et al. Diabetes Technology & Therapeutics
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
- (2015) Reinhard H. A. Becker et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Menopause
- (2015) Traci A. Takahashi et al. MEDICAL CLINICS OF NORTH AMERICA
- Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients
- (2015) Shereen Aleidi et al. SAUDI PHARMACEUTICAL JOURNAL
- Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
- (2014) Lesley J. Scott DRUGS
- Effects of GLP-1 on appetite and weight
- (2014) Meera Shah et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro
- (2014) Robert Root-Bernstein et al. Frontiers in Endocrinology
- Sex differences in type 2 diabetes: focus on disease course and outcomes
- (2014) Lisa Arnetz et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late
- (2013) Madonna M. Roche et al. DIABETES CARE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Effect of gender on treatment outcomes in type 2 diabetes mellitus
- (2013) J.B. McGill et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis
- (2013) Franck Mauvais-Jarvis et al. ENDOCRINE REVIEWS
- Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
- (2013) Giuseppe Seghieri et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Targeted estrogen delivery reverses the metabolic syndrome
- (2012) Brian Finan et al. NATURE MEDICINE
- Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index
- (2012) Richard Pencek et al. POSTGRADUATE MEDICINE
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
- (2011) A. J. Garber DIABETES CARE
- One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
- (2010) M. Buysschaert et al. DIABETES & METABOLISM
- Risk factors for cardiovascular disease in women with diabetes
- (2010) Christine Maric Gender Medicine
- Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity
- (2008) R Pasquali et al. INTERNATIONAL JOURNAL OF OBESITY
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now